Today: 10 June 2026
Browse Category

NASDAQ:CABA 31 October 2025 - 4 May 2026

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Cabaletta Bio shares surged 32% after the company reported early results from its cell-therapy trial and priced a $150 million stock offering with participation from Eli Lilly and others. Two of four pemphigus vulgaris patients showed clinical activity with rese-cel, its experimental CAR-T therapy. The company expects to fund operations into mid-2027. New data will be presented at the ASGCT meeting on May 14.
4 May 2026
····
Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape

Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape

Cabaletta Bio shares rose about 11% premarket Thursday after insider-buying reports, trading at $2.60 versus Wednesday’s $2.34 close. CEO Steven Nichtberger bought 45,000 shares Jan. 21, with other executives and directors also purchasing stock, SEC filings show. Trading volume Wednesday hit 2.09 million shares. The company is developing an experimental CD19 CAR-T therapy for autoimmune diseases.
22 January 2026
·
Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Cabaletta Bio shares surged up to 46% on Oct. 31, closing at $3.61 after strong CAR-T therapy data, with trading volume hitting 35.7 million shares. Phase 1/2 results showed major improvements in myositis and systemic sclerosis, and durable lupus nephritis remissions. The company remains pre-revenue, holding $194.7 million cash as of June 30. Wall Street analysts mostly rate CABA a “Buy,” with targets averaging $13–15.
31 October 2025
··

Stock Market Today

  • Darden Restaurants (DRI) Valuation Analysis Amid Mixed Share Performance
    June 10, 2026, 8:30 AM EDT. Darden Restaurants (DRI) shares traded around $200.91, up 1.3% last week and 2.4% over the month, yet down 4.2% year-over-year, reflecting mixed recent performance. The company, a major U.S. casual dining operator, shows a valuation score of 4 out of 6, indicating it is mostly undervalued. A Discounted Cash Flow (DCF) model projects an intrinsic value of $252.24 per share, suggesting the stock is approximately 20.3% undervalued based on future free cash flow estimates to 2035. This analysis may offer investors an opportunity amid ongoing consumer spending scrutiny and sector cost pressures.

Latest articles

IREN Stock Pauses as Nvidia Rally Cools Before Holiday

IREN Shares Fall Again; Microsoft AI Cloud Agreement Still in Focus

10 June 2026
IREN plunged 8.73% to $54.02 Tuesday and slid another 3.72% premarket as investors weighed Wall Street’s bullish calls on its AI cloud buildout against a tech and crypto selloff; the stock’s fate now hinges on IREN’s ability to deliver Microsoft- and Nvidia-linked AI infrastructure on schedule, with the Microsoft contract at risk if timelines slip.
Archer Aviation Stock Falls After ARK Sale as ACHR Bulls Face Fresh eVTOL Test

Archer Aviation Stock Falls After ARK Sale as ACHR Bulls Face Fresh eVTOL Test

10 June 2026
Archer Aviation plunged 7.16% to $5.32 after ARK Invest dumped over 2.2 million shares across three ETFs, intensifying pressure on a stock already sensitive to funding and FAA certification risks; shares traded at $5.19 premarket as investors weighed cash burn, ongoing losses, and the urgent need for operational milestones before capital runs thin.
Tesla Drops Pre-Market as SpaceX IPO Buzz Puts Pressure on Musk Plays

Tesla Drops Pre-Market as SpaceX IPO Buzz Puts Pressure on Musk Plays

10 June 2026
Tesla slid 3% to $396.68 Tuesday and dropped another 1.26% premarket as SpaceX’s record $75 billion IPO, with over $250 billion in demand, gives investors a new Musk-linked bet, raising fears capital will rotate out of Tesla and other high-growth tech stocks just as Tesla’s next phase relies on heavy AI and robotaxi spending.
Go toTop